To ask His Majesty's Government what assessment they have made of the implementation of the UK-USA Free Trade Agreement.

To ask His Majesty's Government what assessment they have made of the implementation of the UK-USA Free Trade Agreement.

To ask His Majesty's Government, further to the reply by Lord Livermore on 14 July (HL Deb col 562), what legal advice they have received on the compatibility of a revised UK-EU Trade and Cooperation Agreement with the UK's obligations under the Comprehensive and Progressive Agreement for Trans-Pacific Partnership and UK-US...

To ask His Majesty's Government, further to the reply by Lord Livermore on 14 July (HL Deb col 562), what legal advice they have received on the compatibility of a revised UK-EU Trade and Cooperation Agreement with the UK's obligations under the Comprehensive and Progressive Agreement for Trans-Pacific Partnership and UK-US...

The UK and US Governments announced a pharmaceuticals trade deal in December 2025.

The UK and US Governments announced a pharmaceuticals trade deal in December 2025.

This short briefing summarises the UK's progress in negotiating new free trade agreements.

This short briefing summarises the UK's progress in negotiating new free trade agreements.

New clause 12, discussed with new clauses 56 and 84, debated and withdrawn. New clause 14, discussed with new clauses 79 and 80, debated and withdrawn. New clause 15, discussed with new clause 76, debated and withdrawn. New clause 16, discussed with new clauses 17, 18 and 89, debated and withdrawn. New clause 18 negatived on division (1 to 7). New clause 25, discussed with new clauses 62, 63 and 64, debated and withdrawn. New clause 28 debated and withdrawn. Written evidence reported to the House.

New clause 12, discussed with new clauses 56 and 84, debated and withdrawn. New clause 14, discussed with new clauses 79 and 80, debated and withdrawn. New clause 15, discussed with new clause 76, debated and withdrawn. New clause 16, discussed with new clauses 17, 18 and 89, debated and...

To ask the Secretary of State for Business and Trade, if he will make it his policy to seek closer trade relations between the Northern Ireland agri-food market and the US.

To ask the Secretary of State for Business and Trade, if he will make it his policy to seek closer trade relations between the Northern Ireland agri-food market and the US.

Main estimates 2026-27. Second estimates day (part two). Motion that, for the year ending with 31 March 2027, for expenditure by the Department of Health and Social Care: (1) further resources, not exceeding £108,291,452,000, be authorised for use for current purposes as set out in HC 1855 of Session 2024–26, (2) further resources, not exceeding £7,899,179,000, be authorised for use for capital purposes as so set out, and (3) a further sum, not exceeding £115,924,112,000, be granted to His Majesty to be issued by the Treasury out of the Consolidated Fund and applied for expenditure on the use of resources authorised by Parliament. Question deferred. Resolved.

Main estimates 2026-27. Second estimates day (part two). Motion that, for the year ending with 31 March 2027, for expenditure by the Department of Health and Social Care: (1) further resources, not exceeding £108,291,452,000, be authorised for use for current purposes as set out in HC 1855 of Session 2024–26,...

I thank the Backbench Business Committee for granting this debate on the NHS estimates and, in particular, the impact of the UK-US pharmaceutical deal.

Let me start by briefly talking about the estimates themselves. I am sure that every Member has a copy of them; I have one every year. Given...

I thank the Backbench Business Committee for granting this debate on the NHS estimates and, in particular, the impact of the UK-US pharmaceutical deal.

Let me start by briefly talking about the estimates themselves. I am sure that every Member has a copy of them; I have one every year. Given...

The hon. Member is making an excellent speech, and is trying to draw out the details of this deal; I am glad that one of her constituents drew her attention to it. I was lobbied by Karl Claxton at the University of York, who described this deal as an existential...

The hon. Member is making an excellent speech, and is trying to draw out the details of this deal; I am glad that one of her constituents drew her attention to it. I was lobbied by Karl Claxton at the University of York, who described this deal as an existential...

I believe that by the end of my speech, the hon. Gentleman and I will be in violent agreement, if we are not already. There is one more aspect of this, incidentally: the supply chains deal, which I understand is being crafted. We do not have time to go into...

I believe that by the end of my speech, the hon. Gentleman and I will be in violent agreement, if we are not already. There is one more aspect of this, incidentally: the supply chains deal, which I understand is being crafted. We do not have time to go into...

I commend the hon. Lady on the speech she is making. It is really important that we talk about the disadvantages of this deal, and there is a clear disadvantage to Northern Ireland. Access to everyday medicines in rural communities in Strangford and across Northern Ireland will be inhibited, so...

I commend the hon. Lady on the speech she is making. It is really important that we talk about the disadvantages of this deal, and there is a clear disadvantage to Northern Ireland. Access to everyday medicines in rural communities in Strangford and across Northern Ireland will be inhibited, so...

That is a really good point. I will come back to generics, which make up nine in 10 of the medicines that the NHS uses. There is also an issue of devolution here, which I am sure other Members will cover. At the moment it is very complex, and it...

That is a really good point. I will come back to generics, which make up nine in 10 of the medicines that the NHS uses. There is also an issue of devolution here, which I am sure other Members will cover. At the moment it is very complex, and it...

Does the hon. Lady agree that the Government’s failure to publish the impact assessment means that NHS authorities across the country do not know how much this deal will cost them? My constituents in Somerset cannot get a GP appointment or see an NHS dentist. That is far more important...

Does the hon. Lady agree that the Government’s failure to publish the impact assessment means that NHS authorities across the country do not know how much this deal will cost them? My constituents in Somerset cannot get a GP appointment or see an NHS dentist. That is far more important...

The hon. Gentleman is absolutely right, and that lack of transparency is the nub of my speech today.

There are some potential positives in the deal. At the 10 February sitting of the Business and Trade Committee, a representative of the Association of the British Pharmaceutical Industry said that zero tariffs...

The hon. Gentleman is absolutely right, and that lack of transparency is the nub of my speech today.

There are some potential positives in the deal. At the 10 February sitting of the Business and Trade Committee, a representative of the Association of the British Pharmaceutical Industry said that zero tariffs...

I thank the Chair of the Health and Social Care Committee, the hon. Member for Oxford West and Abingdon (Layla Moran) for her comments.

Life sciences are one of the country’s great strengths. We have world-leading universities, brilliant researchers, innovative companies, NHS experts and public investment. The life sciences support high-skilled...

I thank the Chair of the Health and Social Care Committee, the hon. Member for Oxford West and Abingdon (Layla Moran) for her comments.

Life sciences are one of the country’s great strengths. We have world-leading universities, brilliant researchers, innovative companies, NHS experts and public investment. The life sciences support high-skilled...

An estimated 229,000 excess deaths by 2036—that is the eye-watering figure that BMJ analysis identifies as the upshot of diverting NHS funding to pay more for pharmaceuticals in response to Trump’s threats.

Estimates day debates exist to scrutinise how public money will be spent before that spending has happened, not least...

An estimated 229,000 excess deaths by 2036—that is the eye-watering figure that BMJ analysis identifies as the upshot of diverting NHS funding to pay more for pharmaceuticals in response to Trump’s threats.

Estimates day debates exist to scrutinise how public money will be spent before that spending has happened, not least...

I must declare an interest as a registered pharmacist for nearly two decades and an expert on pharmacy procurement.

Let be begin by saying that I welcome the UK-US pharmaceutical trade agreement, and also by saying something quite controversial: President Donald Trump is right. We do underpay for drugs—not just our...

I must declare an interest as a registered pharmacist for nearly two decades and an expert on pharmacy procurement.

Let be begin by saying that I welcome the UK-US pharmaceutical trade agreement, and also by saying something quite controversial: President Donald Trump is right. We do underpay for drugs—not just our...

Will the hon. Gentleman to comment on the fact that the NHS pays 10 times the manufacturing costs for over 80% of the licensed medicines that we buy? How is that underpaying?

Will the hon. Gentleman to comment on the fact that the NHS pays 10 times the manufacturing costs for over 80% of the licensed medicines that we buy? How is that underpaying?

I am not sure where the hon. Gentleman’s figures come from. When we look at the drug tariff reimbursement, which is the system that we use to pay, and compare it with the arrangements in other countries, it is clear that we underpay significantly. Perhaps he is referring to something...

I am not sure where the hon. Gentleman’s figures come from. When we look at the drug tariff reimbursement, which is the system that we use to pay, and compare it with the arrangements in other countries, it is clear that we underpay significantly. Perhaps he is referring to something...